Omeros announces positive results from phase 1 study of its lead PDE7 inhibitor
Omeros announced positive results from its Phase 1 study with the lead compound in its OMS527 program. The OMS527 program is developing phosphodiesterase 7 inhibitors for the treatment of addictions and compulsive disorders as well as movement disorders. September 16, 2019